– USA, WI – Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL), today announced that Susan A. Willetts was elected to the company’s board of directors, effective November 6, 2014. Ms. Willetts also will serve as a member of the CDI board’s audit committee.
Ms. Willetts has been an advisory director of Goldman, Sachs & Co. since July 2011. Prior to July 2011 she was a partner. She joined the firm in the Investment Banking Division in 1989, was named managing director in 1996 and partner in 2002. Prior to joining Goldman Sachs, Ms. Willetts worked at Microdot for five years, most recently as treasurer, and at Northwest Industries for three years. She is on the board of the Chicago Botanic Garden, where she served as chair from 2009 to 2012. Ms. Willetts has been a member of the Economic Club of Chicago since 2004 and became a member of The Chicago Network in 2008. She served on the board of The Field Museum from 1998 to 2006. She earned a BA from Dartmouth in 1977 and an MBA from Northwestern University in 1981.
Susan Willetts said, “Innovation is critical in the field of human healthcare, and I believe that CDI is uniquely positioned to make a significant impact with its technology, patent portfolio and deep expertise. I am pleased to be joining CDI’s board of directors, and I look forward to helping guide the growth of this expanding company.”
Bob Palay, chief executive officer and chairman of the board of CDI, said, “Susan brings to our board deep business experience gained from many years in successful leadership positions. She is a tremendous addition to our board, and we are pleased to have a person of her accomplishments join us.”
About Cellular Dynamics International, Inc.
Cellular Dynamics International, Inc. (CDI) is a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications. CDI’s proprietary iCell Operating System (iCell O/S) includes true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell Products). CDI’s iCell O/S products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use our iCell O/S products, among other purposes, for drug discovery and screening; to test the safety and efficacy of their small molecule and biologic drug candidates; for stem cell banking; and in the research and development of cellular therapeutics. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI’s facilities are located in Madison, Wisconsin, with a second facility in Novato, California.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.